key: cord-0965390-2pvv9pn8 authors: Hoertel, N.; Blachier, M.; Limosin, F.; Sanchez-Rico, M.; Blanco, C.; Olfson, M.; Luchini, S.; Schwarzinger, M.; Leleu, H. title: Optimizing SARS-CoV-2 vaccination strategies in France: Results from a stochastic agent-based model date: 2021-01-20 journal: nan DOI: 10.1101/2021.01.17.21249970 sha: aeddc746b9dab29a23690b7ccca85e3b51cd4239 doc_id: 965390 cord_uid: 2pvv9pn8 The COVID-19 pandemic is a major global societal, economic and health threat. The availability of COVID-19 vaccines has raised hopes for a decline in the pandemic. We built upon a stochastic agent-based microsimulation model of the COVID-19 epidemic in France. We examined the potential impact of different vaccination strategies, defined according to the age, medical conditions, and expected vaccination acceptance of the target non-immunized adult population, on disease cumulative incidence, mortality, and number of hospital admissions. Specifically, we examined whether these vaccination strategies would allow to lift all non-pharmacological interventions (NPIs), based on a sufficiently low cumulative mortality and number of hospital admissions. While vaccinating the full adult non-immunized population, if performed immediately, would be highly effective in reducing incidence, mortality and hospital-bed occupancy, and would allow discontinuing all NPIs, this strategy would require a large number of vaccine doses. Vaccinating only adults at higher risk for severe SARS-CoV-2 infection, i.e. those aged over 65 years or with medical conditions, would be insufficient to lift NPIs. Immediately vaccinating only adults aged over 45 years, or only adults aged over 55 years with mandatory vaccination of those aged over 65 years, would enable lifting all NPIs with a substantially lower number of vaccine doses, particularly with the latter vaccination strategy. Benefits of these strategies would be markedly reduced if the vaccination was delayed, was less effective than expected on virus transmission or in preventing COVID-19 among older adults, or was not widely accepted. The COVID-19 pandemic is a major global societal, economic and health threat. In the initial absence of a vaccine or an effective treatment for COVID-19, most countries have responded with a variety of non-pharmaceutical interventions (NPIs), such as physical distancing, mandatory use of face masks, and repeated lockdowns, to curtail viral transmission by reducing contact rates and to avoid the overwhelming of healthcare services. These measures have been effective in reducing disease transmission, but have led to negative psychological 1-3 , medical 4,5 , economic, and social consequences. 6, 7 Recent phase III trials have demonstrated that three vaccines could prevent development of severe form of SARS-CoV-2 infection and reduce disease transmission, raising hopes for a decline of the pandemic. [8] [9] [10] However, beyond vaccine efficacy, the success of a vaccine depends on the vaccination program strategy, including the identification of the priority target population, its availability timelines constrained by the production and distribution capabilities, and its rates of uptake in the target population. In the context of limited supply of COVID-19 vaccines, there is a need to define priority groups within the populations. In France, COVID-19 vaccine acceptance in the general population ranges from 50% to 60%, with substantial variability across age groups. [11] [12] [13] [14] Therefore, determining vaccination program strategies that optimally mitigate the pandemic according to these parameters is urgently needed. In this report, we built upon a stochastic agent-based microsimulation (ABM) model of the COVID-19 epidemic in France, 15 and projected the potential impact of different vaccination strategies on COVID-19 cumulative incidence, mortality, and number of hospital admissions. Specifically, because NPIs impose considerable burdens on the population and the economy, we examined whether prioritizing vaccination of older adults or individuals with medical conditions, who are the most prone to develop severe COVID-19, 16 would All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249970 doi: medRxiv preprint permit lifting NPIs, based on a sufficiently low cumulative mortality and number of hospital admissions. We built upon a stochastic agent-based model of the epidemic of COVID-19 in France that previously showed adequate calibration and validation. 15 Briefly, this model includes (i) a realistic synthetic population generated with demographic characteristics, medical comorbidities and household structure representative of the French general population, [17] [18] [19] [20] (ii) a social contact network among the individuals, each with a geolocalized activity sequence over the day, taking into account co-location probability and duration, including contacts with family members, extended family members or friends (at home or at bars and restaurants), contacts at school or at work, and during public transport or grocery shopping or cultural activities, and (iii) a disease model, which translates the edge weights in the social contact network into infection probability of the edge over the day. The model parameters are summarized in eTable 1. We updated the contamination risk and proportion of undiagnosed cases of our initial model 15, 21 and included data on SARS-CoV-2 seroprevalence in May 2020 in France. 22 Outcomes Outcomes included cumulative incidence, mortality, and number of hospital admissions. The probabilities of hospital admission or death were stratified by age and adjusted for comorbidities, including, obesity, diabetes, chronic cardiac diseases, and chronic respiratory diseases, based on hazard ratios calculated using data from Institut Pasteur 23 and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 54.8%-80.6%), in individuals aged 18 years and over, we conducted sensitivity analyses using efficacy data of this vaccine. Estimated COVID-19 vaccine acceptance was based on a discrete choice experiment conducted in a large sample representative of the French population aged 18-64 years. 11 This study showed that vaccine uptake would be expected to assume an inverted U-shape relationship with advancing age. We assumed in our model that individuals accepting the vaccine would be vaccinated. In the absence of specific data, we also assumed that vaccine All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We examined whether the model had adequate calibration, i.e., whether it was able to adequately reproduce retrospectively the course of the epidemic until December 20 th , 2020, based on R² and Normalized Root Mean Squared Error (NRMSE) for weekly mortality and hospital admissions, and visual comparison between model-predicted and observed mortality and hospital admissions. All scenarios included a full population lockdown between March 17 th , 2020 and May 11 th, 2020, followed by a progressive return to 75% of the pre-pandemic social contacts level until July 1 st , 2020, except at schools, which remained closed during that period, and a 30% rate of workers using telework. Following prior epidemiological trends, 28 we assumed that SARS-CoV-2 infection was associated with a 23% reduction in disease transmission due to warm weather between July 1 st , 2020 and September 25 th , 2020. This latter date was chosen because it marked a significant drop in temperature in France and was quickly followed by a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted significant increase in the number of cases. On September 1 st , 2020, schools reopened for all students and telework use decreased to 16% based on Google Mobility Reports for France. 24 Based on data from Santé Publique France, 24 we considered that face mask use at work, in public transport, during grocery shopping and for cultural events increased from 15% to 70% between April 4 th and September 1 st , 2020, and remained at this level hereafter. We assumed a limited use of face mask (i.e., 30%) in households or with friends or extended family members during this period and hereafter. Curfew was instated on October 17 th , 2020, which has led to cancelation of all cultural events and was assumed to reduce social contacts with friends and extended family members by 50%. We considered that this curfew would last until January 15 th , 2021. A second less stringent lockdown was instated between October 30 th and December 15 th , 2020, with schools and workplaces remaining opened. We assumed that 50% of individuals worked remotely from home during this second lockdown period and that this rate will be of 30% during the curfew after the second lockdown lifting. To examine whether any vaccination scenario could allow for a lifting of NPIs, we assumed that from January 15 th , 2021, social behaviors would return to those observed before the COVID-19 epidemic, with full discontinuation of all NPIs, and examined associated cumulative incidence, mortality, and number of hospital admissions. In our model, we considered that a vaccination strategy would allow for the discontinuation of NPIs if it was associated with (i) a cumulative number of deaths lower than 17 per 100,000 and (ii) a cumulative number of hospital admissions below 240 per 100,000, between December 27 th , 2020 and August 1 st , 2021. The first threshold corresponds to the mean plus two standard deviations of the total number of deaths observed in France between January 15 th , 2020 and August 1 st for the years 2015 to 2019, representing the threshold above which an increase in death could be considered significant. Given that hospital-bed capacity is 600 per 100,000 inhabitants in France 24 and that the mean duration of a hospitalization for COVID-19 is about 1 0 21 days, 24 the second threshold corresponds to a maximum hospital-bed occupancy rate for COVID-19 of 5% between December 27 th , 2020 and August 1 st , 2021. We chose this threshold because current hospital-bed occupancy by patients with COVID-19 is currently estimated at 6.3% (25,000/400,000) of the total number of hospital beds in France. 24 Given the limited production and distribution capabilities for COVID-19 vaccines, it is expected that vaccinating the full non-immunized French population aged 18 years or older would probably require several months, even with three vaccines. Because our main aim was to examine whether different vaccination strategies would allow for lifting NPIs, rather than make questionable assumptions on time for vaccinating the population, we considered that vaccination in each scenario would be achieved by January 15 th , 2021 and calculated the number of vaccine doses needed (considering 2 doses per individual) in each scenario. Next we examined the impact of different vaccination scenarios according to the choice of the non-immunized adult populations to prioritize for vaccination: (i) no vaccination, (ii) vaccination of the full population, (iii) vaccination of adults aged less than 65 years, (iv) vaccination of adults aged more than 45 years, (v) vaccination of adults aged less than 35 years or more than 65 years, (vi) vaccination of adults aged more than 65 years, (vii) vaccination of adults aged more than 55 years with mandatory vaccination of adults aged more than 65 years (assuming that it would lead to a 90% vaccination rate in this population), and (viii) vaccination of individuals at higher risk for severe SARS-CoV-2 infection (i.e. adults aged more than 65 years and those with medical conditions associated with increased risk of severe COVID-19 16 ). Two factors drove the choice of these scenarios: (i) the substantial risk of severe disease in adults aged more than 65 years and in those with medical conditions, and (ii) the higher expected vaccination uptake in younger than in older adults ( Table 1) . 1 1 We performed several sensitivity analyses for the four following scenarios: (i) vaccination of the full adult non-immunized population, (ii) vaccination of adults aged more than 45 years, (iii) vaccination of adults aged more than 55 years with mandatory vaccination of adults aged more than 65 years, and (iv) vaccination of at-risk individuals. First, we considered a 10% lower rate of vaccine uptake than that expected. 11 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The model calibrated well, based on a good visual fit between observed and modelpredicted hospital admissions and mortality (Figure 1 ). In addition, R² and NRMSE were 0.96 and 5.6% for weekly hospital admissions, and 0.96 and 4.6% for weekly mortality, respectively. Based on our model, we projected that the cumulative COVID- 19 decrease in cumulative hospital-bed occupancy ( Table 2) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For scenarios in which the vaccination targeted a specific adult non-immunized population, our findings suggest that all of them, except the scenarios targeting only adults aged more than 65 years, or only at-risk individuals, or only individuals aged over 65 years or under 35 years, would virtually allow lifting of NPIs, if they were applied immediately, based on a cumulative mortality rate lower than 17 per 100,000 and a cumulative hospital admission rate lower than 240 per 100,000 ( Table 2, Table 1) . Table 3) A reduction of 10% of the expected rate of vaccine uptake would be associated with a substantial increase in mortality and hospital-bed occupancy, and would prevent discontinuation of NPIs for all strategies, unless the full adult non-immunized population was vaccinated. Lower effect of the vaccine on preventing COVID-19 among individuals aged 75 years or older (i.e. 50% instead of 94.7%) would be associated with a substantially higher cumulative mortality and would prevent the lifting of NPIs in all scenarios, except with the vaccination of the full non-immunized adult population or of the subpopulation aged over 45 years. Similarly, lower vaccine efficacy on carriage (i.e. 50% instead of 100%) would also lead to a cumulative mortality higher than the threshold of 17 per 100,000 for all vaccination strategies, except for those targeting the full non-immunized adult population or the subpopulation of adults aged over 45 years. Delayed vaccination of the target population or a less effective vaccine, as reported for ChAdOx1 nCoV-19, would result in worse outcomes, including higher incidence, mortality, and hospital-bed occupancy, and would not allow for All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; 1 4 discontinuation of NPIs with current expected rates of vaccination acceptance. Varying all model parameter values by ±20% for the scenario 'vaccination of the full adult nonimmunized population' would change the cumulative number of hospital admissions by ± 16.2% and the cumulative mortality by ± 18.5%, suggesting the robustness of the differences observed across scenarios. In this report, we built upon a stochastic agent-based microsimulation model of the COVID-19 epidemic in France 15 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; 1 5 Current vaccination plans in France 33 call for a multi-step approach by decreasing age groups, with priority given for the available vaccine doses to individuals aged over 80 years and healthcare workers. Step 2 of this plan involves vaccinating people over 75 years, then those older than 65 years and having medical conditions increasing the risk of severe SARS-CoV-2 infection, 24 and finally all other adults between 65 and 74 years of age. While this strategy is likely to markedly reduce mortality and hospital-bed occupancy, 24 our results suggest that it would not be sufficient to allow discontinuing NPIs. Even once step 2 is achieved, NPIs would still have to be enforced to prevent a rebound of the epidemic. In our model, an additional 35,235 deaths [95% prediction interval: 31,639; 38,832] in France were projected if NPIs were discontinued after vaccinating only adults aged over 65 years. This result can be explained by two factors. First, the vaccine acceptance in this age group is estimated to be 68%, leaving a substantial fraction of this population at risk of being infected. Second, model results suggest that despite two successive epidemic rebounds, vaccinating only 68% of the individuals aged over 65 years would not be sufficient to produce herd immunity, especially with a high infection rate among younger adults. Indeed, while vaccinating individuals aged over 65 years substantially reduces mortality and the number of hospital admissions compared to the absence of vaccination, it would only reduce by 19% the cumulative COVID-19 incidence. This finding reflects the individual benefit of the vaccination in the absence of herd immunity, with 32% of the population remaining unprotected. Conversely, in a scenario where vaccination coverage rate was 90% for this age group (for example in case of mandatory vaccination), most individuals would benefit from the individual protection provided by a vaccine. Although the scenario of a mandatory vaccination for adults aged over 65 years and a priority given to adults between 55 and 65 years of age may be discussed from an ethical perspective, 33 our results suggest that it would be associated with a cumulative mortality rate of 9 [95% interval: 7; 10] per 100,000 and a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; 1 6 cumulative number of hospital admissions of 55 [95% interval: 46; 64], allowing for discontinuation of NPIs, which are associated with substantial negative psychological, 1-3 medical, 4,5 economic, and social consequences 6, 7 in the full population. There are still some uncertainties regarding the efficacy and the acceptance of COVID-19 vaccines. First, it is not yet known whether vaccine efficacy is similar in individuals aged over 75 years and in younger adults. In our model, lower efficacy among individuals aged 75 years or older (i.e. 50% instead of 94.7%) would be associated with a substantially higher cumulative mortality and would prevent the lifting of NPIs with all vaccination strategies, except those including vaccination of the full non-immunized adult population or of the subpopulation of adults aged over 45 years. Second, estimated acceptance might be lower than expected. Reducing expected vaccine acceptance by 10% did not yield substantially different results when vaccinating the full population, but did make discontinuing NPI less likely with all other scenarios. However, vaccine acceptance might be higher than expected as people learn more about vaccine effectiveness. 34 Finally, there is debate as to whether vaccines would protect against asymptomatic SARS-CoV-2 carriage, 9 as clinical trial endpoints were based on COVID-19 diagnosis and not on routine RT-PCR. [8] [9] [10] In our model, lower vaccine efficacy on carriage (i.e. 50% instead of 100%) would lead to a substantially higher cumulative mortality, preventing discontinuation of NPIs in all vaccination strategies, except for those including vaccination of the full non-immunized adult population or of the subpopulation of adults aged over 45 years. Our study has several limitations. First, as with all modeling studies, we rely on existing knowledge and current assumptions, that might need to be revised with advances in knowledge of this novel disease. Second, there are still uncertainties concerning vaccine effectiveness, availability, and acceptance. Although we used real world data for acceptance and data from large phase III clinical trials for vaccine efficacy, we cannot rule out All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. Benefits from these strategies would nonetheless be markedly reduced if the vaccination was delayed, or less effective than expected in preventing virus transmission and COVID-19, or if most people do not accept vaccination. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; The dotted lines represent the uncertainty r prediction interval) stemming from the uncertainty in the parameter values. 2 2 o COVID-19 y range (95% All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; 2 4 In millions * Includes 30% of 45-65 adults that are estimated to have comorbidities putting them at risk of severe COVID-19. We considered that a vaccination strategy would allow for the discontinuation of NPIs if it was associated with (i) a cumulative number of deaths lower than 17 per 100,000 and (ii) a cumulative number of hospital admissions below 240 per 100,000, between December 27 th , 2020 and August 1 st , 2021 (see Methods). In millions * Includes cases that occurred between January 15 th and April 15 th 2021, prior to vaccination. Number of doses are calculated while considering that immunized adults who had COVID-19 will not receive the vaccine. We considered that a vaccination strategy would allow for the discontinuation of NPIs if it was associated with (i) a cumulative number of deaths lower than 17 per 100,000 and (ii) a cumulative number of hospital admissions below 240 per 100,000, between December 27 th , 2020 and August 1 st , 2021 (see Methods). eFigure2. Model-predicted daily incidence in France in the scenario considering that NPIs present on December 15 th maintained until April 15 th and then discontinued after that date. The dotted lines represent the uncertainty range (95% predictio stemming from the uncertainty in the parameter values. 2 9 would be tion interval) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany Anxiety and depression in the Republic of Ireland during the COVID-19 pandemic LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden a population-based, observational study. The Lancet Public Health Economic and social consequences of human mobility restrictions under COVID-19 Global socio-economic losses and environmental gains from the Coronavirus pandemic Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine vaccine hesitancy in the French population of working age: a survey experiment of vaccine characteristics Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Sharp rise in vaccine hesitancy in a large and representative sample of the French population: reasons for vaccine hesitancy A stochastic agent-based model of the SARS-CoV-2 epidemic in OpenSAFELY: factors associated with COVID-19-related A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18-to 74-year-old individuals: the French Nutrition and Health Survey Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions Personnes prises en charge pour maladie coronaire chronique en 2017 Population totale par sexe et âge au 1er janvier 2020, France métropolitaine A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18-to 74-year-old individuals: the French Nutrition and Health Survey Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions La consommation de tabac en France: premiers résultats du baromètre santé 2017 prévalence, traitement et contrôle en 2015 et évolution depuis 2006. Revue de Biologie Médicale The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae COVID-19 Évolution des commerces à Paris No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted COVID-19-report 3: transmissibility of 2019-nCoV Estimating the burden of SARS-CoV-2 in France OpenSAFELY: factors associated with COVID-19-related Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The lancet infectious diseases Parcours hospitalier des patients atteints de la Covid-19 lors de la première vague de l'épidémie No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Non-immunized adults over 55 years with mandatory vaccination of those over 65 years All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 20, 2021.